First Dallas Securities Inc. Sells 325 Shares of Gilead Sciences, Inc. (GILD)

First Dallas Securities Inc. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 7,025 shares of the biopharmaceutical company’s stock after selling 325 shares during the period. First Dallas Securities Inc.’s holdings in Gilead Sciences were worth $477,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. GLG LLC boosted its stake in Gilead Sciences by 6.8% in the fourth quarter. GLG LLC now owns 77,104 shares of the biopharmaceutical company’s stock worth $5,521,000 after buying an additional 4,901 shares in the last quarter. Highfields Capital Management LP purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $24,927,000. GLG Partners LP purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $859,000. Hampstead Capital LLP purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $2,936,000. Finally, City Financial Investment Co Ltd purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $8,658,000. 73.99% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (GILD) opened at 73.16 on Friday. The stock’s 50 day moving average is $70.60 and its 200 day moving average is $68.59. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.10. The firm has a market capitalization of $95.55 billion, a P/E ratio of 7.95 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the company earned $3.08 earnings per share. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was originally posted by [[site]] and is the property of of [[site]]. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at [[permalink]].

Several research firms have recently commented on GILD. Jefferies Group LLC reissued a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research report on Tuesday, April 25th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. BMO Capital Markets reiterated a “hold” rating and set a $76.00 target price (up from $75.00) on shares of Gilead Sciences in a report on Wednesday, May 3rd. Finally, Barclays PLC reiterated an “overweight” rating and set a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.31.

In related news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. Insiders have sold 216,609 shares of company stock worth $15,891,851 in the last quarter. 1.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.